Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
10:41am, Monday, 23'rd Feb 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $13.80
01:58am, Monday, 16'th Feb 2026
Shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the fir
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
11:26am, Friday, 13'th Feb 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now?
10:40am, Thursday, 05'th Feb 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
04:05pm, Wednesday, 28'th Jan 2026
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® In
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Wednesday, 28'th Jan 2026
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI)
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
08:00am, Tuesday, 27'th Jan 2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter a
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
10:41am, Thursday, 22'nd Jan 2026
Here is how Amneal Pharmaceuticals (AMRX) and Biohaven Ltd. (BHVN) have performed compared to their sector so far this year.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Average PT from Brokerages
01:15am, Thursday, 22'nd Jan 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equi
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Grows By 28.4%
05:00am, Monday, 19'th Jan 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 6,851,192 s
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
10:40am, Thursday, 15'th Jan 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
11:36pm, Tuesday, 13'th Jan 2026
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts
03:16am, Thursday, 25'th Dec 2025
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat reports. One inv
